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Abstract 
Glaucoma is a critical eye condition that would eventually cause vision loss and 
irreversible blindness due to the damage of optic nerves. High intraocular pressure (IOP) 
is frequently associated with this disease and hence often used as a diagnostic parameter 
for screening and management of glaucoma. Topical anti-glaucoma drug, Prostaglandin, 
has been shown to be effective in lowering IOP with few side effects. However, it was 
also found that Prostaglandin could alter the structural properties of ocular tissue such as 
the cornea. Goldmann Applanation Tonometry (GAT), which has been the clinical 
standard in measuring intraocular pressure in glaucoma patients, is used with assumptions 
that the structural and biomechanical properties of cornea are negligible. The change in 
corneal properties due to drug effect may thus directly interfere the IOP measurements, 
resulting in artificially low IOP readings. Therefore, the purpose of this study is to 
investigate the potential influence of prostaglandin drugs on cornea stiffness and the IOP 
measurement. This is accomplished by treating canine eyes with Prostaglandin analog, 
Bimatoprost at two different concentration; 200nM and 500nM, and vehicle solution was 
applied to the contralateral eyes as controls. GAT was used to measure the IOP of both 
the treated and control eyes. Mechanical testing was then performed on dissected corneal 
strips to determine the treatment effect of the drug on the corneal stiffness. The 
experimental results (n=12) showed that there was a significant reduction in corneal 
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stiffness in lower concentration group but not in the higher concentration group. There 
was no significant difference found in the GAT readings relative to reference IOPs and 
the change of thickness before and after testing was minimal. This suggested that the IOP 
measurement was not significantly altered after a one-day administration of Bimatoprost. 
However, the drug effect was significant only in the lower concentration group proposed 
that there was some confounding factors in the higher concentration group. This result 
could also suggest that the drug effect was more effective at low concentration. One of 
the limitations of this study was the small sample size. Therefore, a larger sample size 
and also a longer drug exposure time would be required to verify the drug effect on 
corneal stiffness and its influence on IOP measurement. Although current study did not 
demonstrate a strong evidence of the drug effect on corneal stiffness and IOP 
measurement, it provided some preliminary data for research direction as well as a good 
framework for future work.  
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Chapter 1:  Introduction 
Glaucoma is a critical eye condition that would eventually cause vision loss and 
irreversible blindness due to the damage of optic nerve. High intraocular pressure (IOP) 
is often, but not always associated with this disease. Therefore, IOP measurement is 
frequently used as a diagnostic parameter for screening and management of the disease. 
Goldmann Applanation Tonometry (GAT) has been the clinical standard in measuring 
IOP with the underlying principle that assumes that the structural and biomechanical 
properties of cornea are negligible. 
 Nonetheless it was shown that topical use of anti-glaucoma drugs, prostaglandin 
(PG) reduces central cornea thickness (CCT) and induces morphological as well as 
biochemical changes in cornea stromal cells.1, 2 Since structural and biomechanical 
properties of the cornea will be greatly affected by the medication3, 4, this suggests that 
PG treatment might indirectly cause IOP measurement errors. The clinical implications of 
this are significant because the reduction of IOP in PG-treated patients might not reflect 
the actual improvement in the disease but the softening of cornea. Recent experimental 
studies have shown a strong correlation between GAT errors and corneal tensile modulus, 
which is consistent with the theoretical prediction that suggested that the differences in 
corneal biomechanics in fact, have greater impact on IOP measurement errors than 
corneal thickness and curvature.5, 6 
  This study is therefore intended to investigate the potential influence of 
prostaglandin drugs on cornea biomechanical properties and the IOP measurement. 
12 
 
Objective: 
(1) To investigate the effect of Prostaglandin on the cornea stiffness  
(2) To examine the effect of Prostaglandin on IOP measurement 
(3) To examine the reduction in collagen content after prostaglandin treatment 
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Chapter 2: Methodology 
Sample Preparation 
First, pairs of fresh canine eyes (N=12) were obtained from Franklin Dog Shelter and 
Adoption Centre and enucleation was completed within one hour postmortem. Before 
dissecting, CCT was measured from the whole globe using ultrasound pachymeter. After 
sterilizing the globes with Provodin-iodine topical antiseptic, the canine eyes will be cut 
at the equator to separate the anterior and the posterior segments. The eyes were dissected 
carefully by cutting around the limbus of the eyes leaving sufficient sclera to be mounted 
on the anterior chamber and mechanical testing. For mechanical testing purposes, more 
sclera will be spared at nasal-temporal direction. The corneal buttons were then rinsed 
properly and placed in wells with culture mediums. 
Ingredients for cornea preserve medium: 
DMEM: 100mL 
Chondroitin sulfate: 1.35g 
Dextran: 8g or P188: 5mL 
Nonessential amino acids: 1 mL 
Fetal bovine serum (FBS): 2 mL 
Penicillin-streptomycin: 1 mL  
HEPES buffer: some to adjust the pH 
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Prostaglandin (PG) analogue, Bimatoprost Treatment 
The culture medium was replaced with fresh medium supplemented with 200nM and 
500nM of Prostaglandin analog, Bimatoprost. In this study, Bimatoprost (Lumigan 
0.01%) was used because this is one of the most potent IOP-reducing medications.8 For 
each pair of canine eyes, either eye was placed into vehicle solution and contralateral eye 
was immersed into medium supplemented with Prostaglandin to observe the treatment 
effect. PG concentrations were chosen based on the protocols used in Weinreb 's studies 
on effect of Latonoprost on scleral permeability.16.  The cornea in culture medium was 
then incubated at 37°C for 24 hours. The calculations below illustrated the volume of 
Bimatoprost to be added into the culture medium to achieve the desired concentrations. 
Calculations: 
Concentration of Bimatoprost = 0.1 mg/mL = 0.1 g/L 
Given: Molecular Weight = 415.58 g 
Concentration of Bimatoprost  = 0.1gL415.58 𝑔𝑚𝑜𝑙 =   2.4063× 10−4𝑚𝑜𝑙𝐿  
     =   0.24063  𝑚𝑀    
Target Concentration: 200nM and 500 nM 
M1V1 = M2V2 (V1 = volume of drug;  V2= volume of preserve medium) 
  
0.24063 x 10-3 V1 = M2 (V2+V1)  
Using cornea preserve medium, V2  = 50 mL  
 
For 200 nM: 
M
2 
= 200 x 10
-9 
M 
V
1 
= 41.592 µL 
For 500 nM: 
M
2 
= 500 x 10
-9 
M 
V
1 
= 104.110 μL 
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Goldmann Applanation Tonometry 
CCT was measured before testing. The cornea was taken out from the wells and mounted 
on anterior chamber for GAT measurement. The experimental setup will be similar to the 
bovine anterior segment perfusion culture model. 7 The anterior chamber used was shown 
below (Figure 1). One of the channels of the anterior chamber was connected to the 
column filled with culture medium to prevent swelling and another to pressure sensor that 
confirmed and monitored the real-time pressure level in the chamber. 
 
 
Figure 1: Anterior chamber for cornea mounting 
 
The IOP measurement protocols was modified from Goldmann applanation techniques 
reported by Tang et al.11 Before applanation, the anterior segment was secured in a 
holder to keep it stationary. Fluorescein dye was applied gently to the cornea surface 
using a sterilized cotton tip to help visualized the correct alignment of Goldmann mires 
under slit lamp examination. Pressure sensor was placed at the same level as the anterior 
chamber. Three pressure levels; 20mmHg, 30mmHg and 40 mmHg were tested. The 
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pressure was altered by adjusting the height of the column. To get GAT readings, the 
tonometer knob was adjusted to make the inner edge of two semicircles slightly touching. 
Each measurement was repeated three times to get an average. The GAT readings were 
then recorded. 
 
                 
Figure 2: IOP measurement using GAT setup in ex- vivo eyes 
 
Mechanical Testing: DMA and Ramp Analysis 
To measure corneal stiffness, a uniaxial tensile test was performed after IOP 
measurement. The protocols were similar to method used by Tang et al.11 The corneal 
strips were excised in the nasal-temporal direction. Sample widths and thicknesses of 
tissues were measured using ultrasound pachymeter before testing. The corneal strip was 
then placed between two testing grips. Half of the sclera was left above the upper grip 
and the part in between the grips was only cornea. The gap distance was adjusted to apply 
Anterior  
chamber 
Column 
GAT 
Pressure 
sensor 
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force on the tissue. The cornea was pre-conditioned before mechanical testing. Two types 
of tests were performed; DMA and Ramp. DMA analysis involved a cyclic loading while 
ramp analysis included uniaxial tensile load. The Rheometric System Analyzer (RSA) 
computed the stress and strain. The experimental data were then saved and analyzed later 
using Matlab simulations. 
 
 
Figure 3: Mechanical testing setup 
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Chapter 3: Results and Discussion 
Goldmann Applanation Tonometry (GAT) 
The GAT readings of three different pressure levels, 20 mmHg, 30mmHg and 40 mmHg 
were compared with reference IOPs to detect the difference. In the lower drug 
concentration group (200nM), the mean GAT readings were slightly lower for every 
pressure levels in the treated eyes as compared to control eyes. After performing a 
student paired t-test on the control and treatment group, it was found that there were no 
significant difference since the p-value for all three pressure levels exceeded p=0.05 
(Table 1 & Figure 1). In the higher concentration group, the reverse trend was observed 
(Figure 2). The mean GAT readings in the treated eyes were surprisingly higher than the 
control groups. However, the differences were also not significant (p>0.05) (Table 2).  
 
Table 1 GAT readings relative to reference IOP in 200nM group 
N=6 GAT (20mmHg) GAT (30mmHg) GAT (40mmHg) 
Treated 11.88±2.68 21.33±4.26 31.06±3.66 
Control 13.72±1.78 22.78±3.46 31.27±4.54 
P-value 0.122 0.287 0.474 
 
Table 2 GAT readings relative to reference IOPs in 500nM group 
N=6 GAT (20mmHg) GAT (30mmHg) GAT (40mmHg) 
Treated 12.89±5.01 21.5±5.86 29.50±7.85 
Control 11.33±4.81 20.2±6.77 28.44±9.17 
P-value 0.243 0.269 0.384 
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Figure 4 GAT readings vs. Reference IOPs in lower drug concentration 
 
In general, the GAT readings for canine eyes were generally 10mmHg lower than the 
reference IOPs (Table 1 & Table 2). By observing the trend from the graph (Figure 1), 
the mean difference was greater in lower pressure levels and the mean GAT values in 
higher-pressure levels converge. Comparing the standard deviation of the mean GAT 
values (Table 1), it was observed that the range also increased with the pressure.  
20 
 
 
Figure 5 GAT readings vs. Reference IOPs in higher drug concentration 
 
In higher drug concentration (500nM), the mean GAT readings consistently showed 
slightly higher values in treated eyes as compared to control. Similar to the lowe 
concentration group, the standard deviations increased with higher-pressure levels (Table 
2).  
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Mechanical Testing: Corneal Stiffness 
After performing dynamic mechanical analysis and ramp analysis, it was observed that 
200nM group showed a reduction in complex modulus and secant modulus in 
prostaglandin-treated eyes (Table 3). The damping ability, tan (δ) increased after 
treatment. These changes were significant (p<0.05) between the treated and control 
group, suggesting a treatment effect of Bimatoprost.  
  
Table 3 Complex modulus, tan delta and secant modulus in lower concentration group 
N=6 Complex Modulus (MPa) Tan (δ) 
Secant Modulus 
(MPa) 
Treated 5.33±1.42 0.18±0.042 6.95±2.95 
Control 6.24±1.90 0.14±0.011 9.53±2.92 
P-value 0.023* 0.042* 0.033* 
 Note: * means p < 0.05 
 
Exposure to higher concentration (500nM) of Prostaglandin showed no significant 
difference (p>0.05) in the complex modulus, tan (δ) and secant modulus (Table 4). 
However, by looking at the trend on the graph (Figure 3), the average of complex 
modulus and secant modulus were higher in treated than the control samples. The average 
damping ability, tan (δ) of the tissue exposed to 500nM Bimatoprost was lower in treated 
group. 
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Table 4 Complex modulus, tan delta and secant modulus in higher concentration group 
N=6 Complex Modulus (MPa) Tan (δ) 
Secant Modulus 
(MPa) 
Treated 5.63±1.99 0.15±0.018 7.74±3.57 
Control 4.63±0.92 0.17±0.015 6.56±1.99 
P-value 0.078 0.110 0.170 
	  
	  
Looking at the figure shown below, two concentration groups actually showed opposite 
trend, which is consistent with results from GAT. However, the higher concentration 
group did not show significance while lower concentration group displayed significant 
reduction in stiffness and increased damping ability. 
 
	  
Figure 6 Comparison of properties between two concentration groups  
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Change in thickness  
The thickness measurement prior to and after testing showed no significant difference 
(p>0.05) in both control and treated group for lower drug concentration. Nevertheless, the 
average thickness reduced slightly before and after testing in general (Table 5). In treated 
group, the standard deviation was consistent before and after testing. In comparison, it 
was found that the standard deviation for the thickness was really large after testing.  
 
Table 5 Group 200nM: Thickness measurement before and after testing 
Thickness (N=6) Treated (µm) Control (µm) 
Before 654.22±103.01 692.95±69.41 
After 643.11±112.73 652.38±138.89 
P-value 0.394 0.199 
 
 
In higher concentration group, the same trend was observed. There were no significant 
difference (p>0.05) but the thicknesses in both treated and control group were reduced as 
well after testing (Table 6). 
 
Table 6 Group 500nM: Thickness measurement before and after testing 
Thickness (N=6) Treated Control 
Before 680.2±68.72 657.17±73.52 
After 642.78±60.39 650.00±64.40 
P-value 0.107 0.372 
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On the other hand, when comparing the treated and control groups in both concentrations, 
it was observed that after testing, prostaglandin treatment at two concentrations caused 
not much difference in the thickness. The thickness before testing was not compared here 
because the measurements were done before prostaglandin treatment and the thickness 
difference simply reflected the variation of corneal thickness in nature.  
 
	  
Figure 7 Change in thickness measurement before and after testing 
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Discussion 
The GAT readings consistently showed that the GAT readings in canine eyes were about 
5-10 mmHg lower than the reference IOP. This observation was supported with Tang et 
al. studies that have also reported the large underestimation of IOP in canine eyes due to 
distinct biomechanical properties from human eyes.6 Since there was no significant 
difference in GAT readings across treated and control group, this suggested that the 
treatment effect of Prostaglandin analogue, Bimatoprost on IOP measurement was not 
observable after drug administration for 24 hours. In addition, the opposite trend 
observed between two different drug concentrations indicated high variability in the 
measurement. This might be partly due to operator's subjectivity in reading the GAT 
measurements. In addition, the swelling of canine eyes caused blurred edges of 
semicircle, making the measurements essentially difficult. It was challenging to measure 
IOP on ex-vivo eyes because the accuracy of measurement was also affected by the 
techniques that have been used to mount the cornea on the anterior chamber. Since there 
was a fixed window size on the chamber, corneas with different sizes could have 
different boundary conditions. Since the cornea is thinnest in the center and its thickness 
increases radially, the size of the window on the anterior chamber caused the applanated 
area essentially different for corneas with distinctive sizes. This could indirectly 
contribute to more variation in the GAT readings.  On the other hand, the upright 
placement of the chamber also created difficulty in keeping the entire cornea moist, as 
solution would accumulate at the bottom part of the corneas.  
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 From the experimental results of lower concentration group, the effect of 
Bimatoprost on corneal modulus was significant. The reduction in corneal stiffness was 
consistent with the results found in a study that showed significant increase in matrix 
metalloproteinase (MMP) activity and decrease in collagen type 1 in corneal stromal later 
after prostaglandin treatment on rabbit corneas for two months.9 It was known that MMP 
is highly responsible for regulation and maintenance of the extracellular matrix (ECM) 
and high MMP activity in cells cause degradation of collagen fibrils. The reduction in 
collagen content might correlate with the lower stiffness observed in the prostaglandin-
treated eyes. 
 However, there could be an alternate explanation for observed treatment effect in 
the low drug concentration group. It was shown that Bimatoprost also reduced central 
corneal thickness; the decrease in thickness might cancel off the effect of corneal 
swelling. Since the control group did not experience the de-swelling effect from the drug, 
a higher stiffness was found for swollen tissues. The smaller modulus found on treated 
group actually reflected unchanged stiffness in normal condition of the cornea due to the 
cancelling effects while stiffness of the control group was elevated due to swollen 
corneas.  
 The experimental result showed no significance found on higher concentration 
group (500nM). There was no known reason for the increased stiffness on treated eyes. 
One of the possible reasoning is that Bimatoprost is more effective at low concentration.  
Literature showed that only small concentration of Bimatoprost was found in aqueous 
humor of the treated eyes. The maximum concentration of Bimatoprost was found to be 
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6.81 ± 1.36 nM one hour post dose and the drug free acid form was found to be 
maximum after 2 hours post dose and had a concentration of 30.9 ±16.41 nM.17 This 
indicated that drug effect could actually work better in a lower concentration profile as 
compared to high concentration. However, the drug mechanism in corneal cells remained 
largely unknown at this point. Although there were contrasting features found between 
the two different concentrations, it was less likely for Bimatoprost to stiffen the corneas. 
Therefore, this suggested the presence of artifacts in high concentration group and a 
confounding factor has yet to be identified. In order to confirm and investigate the 
underlying reason, more experimental data would be required for further detailed 
analysis. 
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Chapter 4: Conclusions and Future Work 
From my studies, it was found that there was no significant difference found in the 
intraocular pressure measurement using Goldmann Applanation Tonometry after 
Prostaglandin treatment. Although the GAT readings showed opposite trend for two 
different concentrations, it was greatly due to the high variability in the measurements. 
Both concentrations revealed a large standard deviation in IOP measurement and the 
difference between the treated and control eyes fell well in that range. Therefore, it could 
not be concluded that if the treatment effect caused a deviation from the reference 
pressure readings. In addition, there were some limitations in the GAT measurement as 
the swollen cornea posed a challenge in matching the blurred inner edges of the 
semicircles. Moreover, GAT measurement relied highly on the operator as a human error 
of a few mmHg might be induced in adjusting the tonometer knob. In the future, a 
different technique such as a portable Tonopen could be used to measure the IOP in 
addition to the GAT. Since Tonopen have a smaller surface area of contact with the 
cornea as compared to the GAT, the issues of boundary conditions could be eliminated 
and induced fewer errors in the measurement. Also, the drug effect might not be apparent 
after a 24 hours-treatment as the cellular mechanism in response to the drug was shown 
to happen in 24 to 72 hours period. Therefore, a longer treatment time could be done in 
the future in order to observe a more obvious drug effect. 
 On the other hand, a statistically significant correspondence was observed 
between the treated eyes and a reduction of stiffness in the lower drug concentration 
group. The complex and secant modulus were both lower in the treated than the control 
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group suggesting that drug effect might actually contribute to cornea softening. However, 
with an opposite trend found on the higher concentration, the drug effect could not be 
confirmed yet. A disparity in experimental results for two different concentrations 
suggested that more drug concentrations should be tested for a better understanding of the 
drug mechanism. A larger sample size should be used in the future to eliminate the 
variability between eyes and it would be easier to identify the confounding factors with 
more experimental data.  
 Moreover, a histology procedure or collagen assay technique could be used for 
quantification of corneal collagen content in order to confirm the correlations found with 
reduction in corneal stiffness. Since the corneal stromal cells were largely composed of 
collagen, the collagen fibrils in the corneas are highly responsible to withstand the 
external loads imposed on them.15 If a reduction in collagen content were observed in the 
corneal cells, the decrease in stiffness would be confirm and better supported. This would 
help to eliminate the alternate explanation that suggested that the smaller modulus was 
due to the de-swelling effect of the treated group since the reduction in corneal stiffness 
hypothesis was merely based on a relative measurement.  
 The experimental result in this study also showed no significant difference in the 
thickness before and after testing. Although this suggested that swollen cornea might not 
be a confounding factor in the study, the swelling could be masked by the prostaglandin 
effect on central corneal thickness and the presence of variability within the same pair of 
eyes. With the small sample size (n=12) used in this study, it was difficult to assure that 
the swelling effect was eliminated.  
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 For future experiment, cell viability of the cornea should also be assessed to 
evaluate the drug effect on the sustainability of living cells in the culture medium since 
the cellular response to the drug is critical to cause the change in corneal biomechanical 
properties.  
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